3/2/2010

The FDA granted orphan-drug designation to Ariad Pharmaceuticals' candidate for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ariad's AP24534 is undergoing an early-stage clinical trial.

Related Summaries